MAARTEN TAAL's Outputs (3)

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B., & Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article
Fuller, A., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Maxwell, J. R., Bingham, S., Vedhara, K., & Abhishek, A. (in press). Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology, Article keae175. https://doi.org/10.1093/rheumatology/keae175

Objective
To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).

Methods
Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.